



Biomarkers in Neurological Disorders

Guest Editor:

Dr. Mamiko Koshiba

1. Engineering Department,
Graduate School of Sciences and
Technology for Innovation,
Yamaguchi University,
Yamaguchi 755-8611, Japan
2. Department of Pediatrics,
Saitama Medical University,
Saitama 350-0495, Japan
3. Graduate School of
Information Sciences, Tohoku
University, Sendai 980-8579,
Japan
4. Research Center of Children's
Environment, Association for
Children's Environment, Tokyo
106-0044, Japan

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

In this century's increasingly complex society, daily stress may be leading to neurological disorders without us realizing it. The recent prosperity of information engineering and sensing/cognitive processing technology is expected to lead to innovation in health prevention and therapy. Biomarkers defined by an interdisciplinary approach between medical biology, physiology, engineering, and any other disciplines are key to solving this challenge. This Special Issue welcomes research articles and review articles on advanced technology and biomarkers for different kinds of neurological disorders.

Dr. Mamiko Koshiba

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)